MedPage Today: Combination treatment promising for certain leukemia patients
UC expert comments on new study
A combination of low-intensity chemotherapy and an antibody-drug conjugate drug showed promise in a phase 2 trial for older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukemia (ALL).
MedPage Today highlighted the study, and patients in the study had a "significant improvement" in their five-year progression-free survival compared to historical data for this patient set, according to the study's authors.
Emily Curran, MD, medical director of the University of Cincinnati Cancer Center Clinical Trials Office and assistant professor of Internal Medicine in UC's College of Medicine, authored a corresponding commentary on the study, published in The Lancet Hematology.
The study "provides impressive results, with survival outcomes that far exceed historic survival data in older adults with acute lymphocytic leukemia," Curran wrote in the commentary.
Read the MedPage Today article.
Featured photo at top: Dr. Emily Curran examines specimens using a microscope in her lab. Photo/Colleen Kelley/UC Marketing + Brand.
Related Stories
Certain weather patterns can trigger migraines
June 8, 2026
Certain weather patterns really do trigger migraine headaches — and the incidence is more common in the Midwest. As WGN 9 in Chicago recently reported, researchers at the University of Cincinnati College of Medicine have identified two specific weather patterns associated with an increased risk of headaches.
Nanofiber multidrug offers new strategy for glioblastoma
June 8, 2026
Science and medical outlets highlight multidrug nanofiber to treat glioblastoma developed by the University of Cincinnati and Johns Hopkins Medicine.
Ad spending ramps up in Senate race
June 8, 2026
Spectrum News turns to a University of Cincinnati political science professor to explain the national interest in the U.S. Senate campaign in Ohio.